The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis

Published:2021-09-04 Issue:1 Volume:40 Page:91-108
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Visser Laurenske A.^ORCID,Folcher Marc^ORCID,Delgado Simao Claudia^ORCID,Gutierrez Arechederra Biotza,Escudero Encarna,Uyl-de Groot Carin A.^ORCID,Redekop William Ken^ORCID

Funder

Horizon 2020

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01081-y.pdf

Reference68 articles.

1. Wallin MT, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–85. https://doi.org/10.1016/S1474-4422(18)30443-5.

2. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336–46. https://doi.org/10.1016/S0140-6736(16)30959-X.

3. Barin L, et al. The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? Mult Scler Relat Disord. 2018;25(May):112–21. https://doi.org/10.1016/j.msard.2018.07.013.